Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
USRE35213E · kind E · reissue
Assignees
Inventors
Key dates
| Filing date | Jul 29, 1993 |
| Grant date | Apr 16, 1996 |
| Priority date | — |
| Expiry date | Jul 29, 2013 |
Classification
- Technology area (CPC —)General
Abstract
Compositions containing PBN, or active derivatives thereof, in a suitable pharmaceutical carrier for administration to a patient, are disclosed for treating or preventing gastric ulceration caused by ingestion of non-steroidal anti-inflammatories. Based on animal studies, the dosage is in the range of 3 to 300 mg/kg and is administered prior to, simultaneously, or shortly after ingestion of the NSAID compounds(s). In the preferred embodiment, the range is between 10 and 30 mg/kg, depending on the dosage unit required to protect the mucosa. The preferred method of administration is orally, alone or in combination with the non-steroidal anti-inflammatory. It is believed that the PBN is also useful alone for treatment or prevention of ulcers, aspects of diarrhea, gastritis, esophagitis, ileitis, and as an analgesic.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.